Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Fenaux, P; Platzbecker, U; Mufti, GJ; Garcia-Manero, G; Buckstein, R; Santini, V; Diez-Campelo, M; Finelli, C; Cazzola, M; Ilhan, O; Sekeres, MA; Falantes, JF; Arrizabalaga, B; Salvi, F; Giai, V; Vyas, P; Bowen, D; Selleslag, D; DeZern, AE; Jurcic, JG; Germing, U; Gotze, KS; Quesnel, B; Beyne-Rauzy, O; Cluzeau, T; Voso, MT; Mazure, D; Vellenga, E; Greenberg, PL; Hellstrom-Lindberg, E; Zeidan, AM; Ades, L; Verma, A; Savona, MR; Laadem, A; Benzohra, A; Zhang, JN; Rampersad, A; Dunshee, DR; Linde, PG; Sherman, ML; Komrokji, RS; List, AF

Fenaux, P (corresponding author), Hop St Louis, 1 Ave Claude Vellefaux, F-75475 Paris, France.; Platzbecker, U (corresponding author), Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Johannisallee 32 A, D-04103 Leipzig, Germany.

NEW ENGLAND JOURNAL OF MEDICINE, 2020; 382 (2): 140

Abstract

Background Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally b......

Full Text Link